TMP-301 is under clinical development by Tempero Bio and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TMP-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TMP-301 overview
TMP-301 (HTL-14242) is under development for the treatment of dystonia, Parkinson's disease, amyotrophic lateral sclerosis, substance use disorders, alcohol use disorders, cocaine use disorder and anxiety. The drug candidate act by targeting metabotropic glutamate receptor 5 (mGluR5). It is administered through oral route. It is developed based on StaR technology and GPCR structure-based drug design (SBDD) platform. It was under development for depression, dyskinesia in Parkinson's disease, autism and other neurological diseases.
Tempero Bio overview
Tempero Bio is a drug development company. Tempero Bio is headquartered in Delaware, the US.
For a complete picture of TMP-301’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
